Le Lan, Tokumaru Yoshihisa, Oshi Masanori, Asaoka Mariko, Yan Li, Endo Itaru, Ishikawa Takashi, Futamura Manabu, Yoshida Kazuhiro, Takabe Kazuaki
Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA.
Gland Surg. 2021 Jan;10(1):154-165. doi: 10.21037/gs-20-571.
High infiltration of Th2 is linked to breast cancer progression and metastasis through the induction of cytokine release and T-cell anergy. The estrogen receptor (ER)-positive subtype, which accounts for 70% of breast cancer, is known to respond less to neoadjuvant chemotherapy (NAC) due to its low potential for proliferation. We hypothesized that Th2 high tumors are highly proliferative, and thus more likely to respond to NAC in ER-positive breast cancer.
We obtained clinicopathological data and overall survival information on 1,069 breast cancer patients from The Cancer Genome Atlas (TCGA). Computational algorithms and CIBERSORT were used to estimate immune cell infiltration. Additionally, xCell was used for validation.
Th2 high tumors did not consistently associate with an unfavorable immune cell composition and tumor immune microenvironment but were found to be significantly elevated in the cancer stage. Th2 high tumors also correlated with high Nottingham pathological grade, as well as with Ki-67 and proliferation score in ER-positive subtypes. High Th2 tumors achieved a pathological complete response (pCR) significantly higher in ER-positive breast cancer.
In conclusion, high levels of Th2 are associated with aggressive features of breast cancer. Th2 levels may be a biomarker in patient selection for NAC in ER-positive breast cancer.
Th2的高浸润通过诱导细胞因子释放和T细胞无能与乳腺癌的进展和转移相关。雌激素受体（ER）阳性亚型占乳腺癌的70%，由于其增殖潜力低，已知对新辅助化疗（NAC）反应较小。我们假设Th2高表达的肿瘤具有高增殖性，因此在ER阳性乳腺癌中更可能对NAC有反应。
我们从癌症基因组图谱（TCGA）获得了1069例乳腺癌患者的临床病理数据和总生存信息。使用计算算法和CIBERSORT来估计免疫细胞浸润。此外，使用xCell进行验证。
Th2高表达的肿瘤并不总是与不良的免疫细胞组成和肿瘤免疫微环境相关，但在癌症分期中显著升高。Th2高表达的肿瘤也与高诺丁汉病理分级相关，以及与ER阳性亚型中的Ki-67和增殖评分相关。高Th2肿瘤在ER阳性乳腺癌中达到病理完全缓解（pCR）的比例显著更高。
总之，高水平的Th2与乳腺癌的侵袭性特征相关。Th2水平可能是ER阳性乳腺癌患者选择NAC的生物标志物。
